{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:21:00Z","timestamp":1773274860859,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004871","name":"Research Foundation of SUNY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pbb.2022.173393","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T02:05:14Z","timestamp":1651457114000},"page":"173393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3758-5917","authenticated-orcid":false,"given":"Sophie R.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-0638","authenticated-orcid":false,"given":"Michelle L.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-7729","authenticated-orcid":false,"given":"Michael","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Wheelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Centner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Glinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Lipari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Budrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-5487","authenticated-orcid":false,"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-1085","authenticated-orcid":false,"given":"Christopher","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.pbb.2022.173393_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2004.09.009","article-title":"Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats","volume":"504","author":"Adamec","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.pbb.2022.173393_bb0015","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/cells9102265","article-title":"The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson's disease","volume":"9","author":"Altwal","year":"2020","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.pbb.2022.173393_bb0020","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.3390\/molecules26195790","article-title":"Role of 5-HT1A receptor in vilazodone-mediated suppression of L-DOPA-induced dyskinesia and increased responsiveness to cortical input in striatal medium spiny neurons in an animal model of Parkinson's disease","volume":"26","author":"Altwal","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","article-title":"Epidemiology of Parkinson's disease","volume":"255","author":"Alves","year":"2008","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","article-title":"L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study","volume":"195","author":"Arai","year":"1995","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pbb.2011.09.009","article-title":"Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by \u03b1- and \u03b2-adrenergic receptor antagonists in hemiparkinsonian rats","volume":"100","author":"Barnum","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pbb.2022.173393_bb0040","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.pbb.2022.173393_bb0045","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","article-title":"Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels","volume":"118","author":"Bido","year":"2011","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.pbb.2022.173393_bb0050","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0055","first-page":"17","article-title":"The amphetamine induced rotation test: a re-assessment of its use as a tool to monitor motor impairment and functional recovery in rodent models of Parkinson's disease","volume":"9","author":"Bj\u00f6rklund","year":"2019","journal-title":"J. Park. Dis."},{"issue":"13","key":"10.1016\/j.pbb.2022.173393_bb0060","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","article-title":"Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson's disease","volume":"30","author":"Bortolanza","year":"2016","journal-title":"Neurotoxicity Res."},{"key":"10.1016\/j.pbb.2022.173393_bb0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuroscience.2018.08.028","article-title":"Differential effects of extended exercise and memantine treatment on adult neurogenesis in male and female rats","volume":"390","author":"Cahill","year":"2018","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.pbb.2022.173393_bb0075","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2022.173393_bb0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","article-title":"Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat","volume":"409","author":"Chambers","year":"2019","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0090","first-page":"II36","article-title":"Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms","volume":"247","author":"Chase","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.pbb.2022.173393_bb1000","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuropharm.2016.07.025","article-title":"Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats","volume":"110","author":"Conti","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173393_bb0095","article-title":"Amantadine for dyskinesia in Parkinson's disease","volume":"2","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson's disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br. Med. Bull."},{"issue":"12","key":"10.1016\/j.pbb.2022.173393_bb0105","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pbb.2022.173393_bb0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1","article-title":"Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine","volume":"34","author":"Deep","year":"1999","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173393_bb0120","first-page":"299","article-title":"Rotation in the 6-OHDA-lesioned rat","volume":"Volume I","author":"Dunnett","year":"2011"},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-008-1135-6","article-title":"Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat","volume":"199","author":"Dupre","year":"2008","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1353-8020(98)00012-1","article-title":"Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system1","volume":"4","author":"Ehringer","year":"1998","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2217\/nmt-2018-0001","article-title":"The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients","volume":"8","author":"Elkurd","year":"2018","journal-title":"Neurodegener.Dis.Manag."},{"issue":"7","key":"10.1016\/j.pbb.2022.173393_bb0145","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173393_bb0155","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuroscience.2012.05.052","article-title":"L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease","volume":"218","author":"Eskow Jaunarajs","year":"2012","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173393_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01345241","article-title":"Effects of glutamate antagonists on the activity of aromatic L-amino acid decarboxylase","volume":"14","author":"Fisher","year":"1998","journal-title":"Amino Acids"},{"key":"10.1016\/j.pbb.2022.173393_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/exnr.1998.6792","article-title":"Behavioral effects of 5-HT2CReceptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Fox","year":"1998","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.pbb.2022.173393_bb0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0195","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.pbb.2022.173393_bb4000","first-page":"9","article-title":"Eksperimental\u2019naia i klinicheskaia","volume":"74","author":"Kapitsa","year":"2011","journal-title":"Farmakologiia"},{"issue":"8","key":"10.1016\/j.pbb.2022.173393_bb0200","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00702-017-1837-1","article-title":"Serotonergic targets for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Lanza","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2022.173393_bb0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2018.06.024","article-title":"Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: implications for L-DOPA-induced dyskinesia","volume":"138","author":"Lanza","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pbb.2022.173393_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2006.05.021","article-title":"Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review","volume":"248","author":"Leroi","year":"2006","journal-title":"J. Neurol. Sci."},{"issue":"38","key":"10.1016\/j.pbb.2022.173393_bb0215","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1523\/JNEUROSCI.1318-16.2016","article-title":"The role of primary motor cortex (M1) glutamate and GABA signaling in l-DOPA-induced dyskinesia in Parkinsonian rats","volume":"36","author":"Lindenbach","year":"2016","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173393_bb0225","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00464567","article-title":"Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants","volume":"77","author":"Lucki","year":"1982","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0235","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0240","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(25)10406-0","article-title":"Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro","volume":"263","author":"Lupp","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","article-title":"Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA","volume":"1046","author":"Maeda","year":"2005","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0250","first-page":"1","article-title":"Prevalence of Parkinson's disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"npj Park.Dis."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ane.12314","article-title":"Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease","volume":"131","author":"Mazzucchi","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"11","key":"10.1016\/j.pbb.2022.173393_bb0260","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.100","article-title":"Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats","volume":"33","author":"Meadows","year":"2018","journal-title":"Mov.Disord."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","article-title":"Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism","volume":"662","author":"Mizoguchi","year":"1994","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.pbb.2022.173393_bb0270","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0275","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173393_bb0280","series-title":"Parkinson's disease: hope through research","year":"2014"},{"key":"10.1016\/j.pbb.2022.173393_bb5000","year":"2011"},{"issue":"8","key":"10.1016\/j.pbb.2022.173393_bb3000","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-017-1823-7","article-title":"The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies","volume":"125","author":"Pagano","year":"2018","journal-title":"J. Neural Transm. (Vienna, Austria : 1996)"},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0285","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.102.034280","article-title":"Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist","volume":"302","author":"Page","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.pbb.2022.173393_bb0290","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.pbb.2022.173393_bb0295","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0300","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1460-9568.1996.tb01228.x","article-title":"Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine","volume":"8","author":"Parsons","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173393_bb0305","series-title":"The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition","author":"Paxinos","year":"2006"},{"issue":"8","key":"10.1016\/j.pbb.2022.173393_bb0310","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2022.173393_bb0315","series-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","author":"Politis","year":"2014"},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0320","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1460-9568.2004.03591.x","article-title":"Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease","volume":"20","author":"Robelet","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","article-title":"Norepinephrine: the redheaded stepchild of Parkinson's disease","volume":"74","author":"Rommelfanger","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.pbb.2022.173393_bb2000","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0330","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0335","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","article-title":"The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder","volume":"11","author":"Sahli","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-2999(70)90194-9","article-title":"Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment","volume":"13","author":"Scatton","year":"1970","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173393_bb0345","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","article-title":"Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia","volume":"7","author":"Sellnow","year":"2019","journal-title":"Acta Neuropathol.Commun."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173393_bb0355","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"14","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.pbb.2022.173393_bb0360","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1172\/JCI133398","article-title":"Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine","volume":"130","author":"Shen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173393_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113327","article-title":"Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in fisher 344 vs.Lewis hemiparkinsonian rats","volume":"330","author":"Steece-Collier","year":"2020","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0375","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0014-2999(92)90634-G","article-title":"The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way","volume":"213","author":"Stoof","year":"1992","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173393_bb0380","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0361-9230(96)00211-0","article-title":"Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum","volume":"41","author":"Takahashi","year":"1996","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.pbb.2022.173393_bb0385","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"NeuroReport"},{"issue":"980","key":"10.1016\/j.pbb.2022.173393_bb0390","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.pbb.2022.173393_bb0395","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"16","key":"10.1016\/j.pbb.2022.173393_bb0400","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/00001756-199511000-00030","article-title":"Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits","volume":"6","author":"Tremblay","year":"1995","journal-title":"NeuroReport"},{"key":"10.1016\/j.pbb.2022.173393_bb0405","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pbb.2022.173393_bb0410","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neures.2012.03.004","article-title":"Amphetamine-induced rotation and l-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study","volume":"73","author":"Tronci","year":"2012","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.pbb.2022.173393_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104807","article-title":"Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: an electrophysiological perspective","volume":"139","author":"Zheng","year":"2020","journal-title":"Neurobiol. Dis."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:42:32Z","timestamp":1758775352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":88,"alternative-id":["S0091305722000727"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173393","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173393"}}